Global biotechnology company Amgen will acquire Dark Blue Therapeutics, a spinout from the University of Oxford, in a deal worth up to $840 million. The acquisition aims to accelerate the development of a new targeted therapy for leukaemia, a type of blood cancer.

Scientists at Oxford created Dark Blue Therapeutics to translate academic discoveries into medicines. The company focuses on therapies that target proteins driving cancer growth. Researchers believe these proteins are difficult to treat with conventional drugs.

However, the team designed a new strategy to block those cancer-causing mechanisms. Consequently, the research opened a potential path toward more precise treatments for blood cancers.

The acquisition will now allow Amgen to expand the programme using its global drug-development capabilities.

Researchers say the project demonstrates how academic discoveries can lead to innovative medicines.

🔬 Oxford Research Built the Scientific Foundation

Several Oxford departments contributed to the scientific discoveries behind the company. Researchers from the Centre for Medicines Discovery, the Nuffield Department of Medicine, and the Radcliffe Department of Medicine played central roles in the work.

In addition, scientists from the Dunn School of Pathology and the Structural Genomics Consortium supported the research effort. These teams combined expertise in chemistry, biology, and structural science.

First, the researchers identified promising molecular targets linked to leukaemia. Then they designed compounds capable of blocking those targets. As a result, the research created the foundation for a potential new cancer therapy.

This collaboration shows how multidisciplinary research can accelerate drug discovery.

💼 Lab282 Partnership Helped Launch the Company

The programme moved from academic research into biotechnology development through Lab282, a partnership designed to transform scientific discoveries into medicines.

Lab282 connects the University of Oxford, drug-discovery company Evotec, Oxford Science Enterprises, and Bristol Myers Squibb. Together, the partners provide funding, expertise, and industry support for early-stage research projects.

Through this collaboration, researchers launched Dark Blue Therapeutics to develop first-in-class small-molecule cancer therapies. The company focused on proteins previously considered difficult to target with drugs.

Therefore, the partnership allowed scientists to advance the project from early discovery toward potential clinical development.

🌍 Acquisition Could Accelerate New Treatments

The acquisition could help accelerate the development of new treatments for acute leukaemia, one of the most challenging blood cancers.

Amgen plans to use its research infrastructure and pharmaceutical development expertise to advance the programme further. Meanwhile, Oxford researchers will continue contributing scientific insights to the project.

Scientists believe the discovery could also influence future cancer research. The same strategy might help target similar proteins involved in other cancers.

Consequently, the deal highlights how collaboration between universities and pharmaceutical companies can transform scientific discoveries into potential therapies for patients.